PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34824002-0	2022	A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).	orteronel	28-37	androgen receptor	Homo sapiens	95-112	
34824002-0	2022	A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).	orteronel	28-37	androgen receptor	Homo sapiens	114-116	
24844235-3	2014	Based on these observations, potent agents targeting the AR axis were developed: 1) inhibitors of CYP17 (a key enzyme in the production of androgens), such as abiraterone and orteronel; 2) AR antagonists that bind to AR and impair AR activation, such as enzalutamide and ARN-509.	orteronel	175-184	androgen receptor	Homo sapiens	57-59	
31017696-13	2019	Furthermore, Prog-induced AR translocation was not affected by treatment with TAK700 or abiraterone, while it was effectively blocked by the AR antagonist enzalutamide, further demonstrating the direct AR activation by Prog.	orteronel	78-84	androgen receptor	Homo sapiens	26-28	
28463227-5	2017	Here, we have demonstrated that CYP17 inhibitors, with the exception of orteronel, can function as competitive AR antagonists.	orteronel	72-81	androgen receptor	Homo sapiens	111-113